Your doctors might recommend switching you to second-line chemotherapy. They’ll do this if the first-line chemotherapy they try on you doesn’t do the job of fully knocking down your mesothelioma. But there’s a problem with second-line chemotherapy. It might not be any more successful than first-line chemotherapy when all is said and done. Researchers in
The Blog
Mesothelioma cells operate much the same as healthy cells in certain regards. But not when it comes to their mitochondrial functions. Researchers think the difference may eventually open a new front for attacks on mesothelioma. Researchers from the from University of Chicago, Northwestern University, City of Hope, University of Maryland and Dana-Farber Cancer Institute have
Taking measurements of CTLA-4 levels in your body may be a useful way to gauge your mesothelioma survival prospects. Researchers from the University of Genoa in Italy looked at CTLA-4 expression in tumor tissues taken from 45 mesothelioma patients and found that the protein may have prognostic value. The scientists observed that more than half
The American Society of Clinical Oncology held its annual meeting in early June. As in prior years, this event drew many top researchers who specialize in mesothelioma. Gathering in Chicago, attendees learned new insights about mesothelioma and received updates about ongoing research. Among the updates given to meeting participants: new information about CRS-207 and FP-1039.
One way you might go about treating mesothelioma is by regulating the transcription factor known as specificity protein 1, while at the same time promoting induction of the mitochondrial cell-death pathway. Researchers from South Korea and China think both can be achieved through the use of a bacterium called manumycin-A. Manumycin-A is derived from Streptomyces
Bisphosphonates can be devastatingly harmful to some women with osteoporosis, but researchers in Japan think one of the ingredients in the latest generation of that drug can be helpful in treating mesothelioma. The ingredient they are looking at is zoledronic acid. The researchers say they are opening a Phase I study of zoledronic acid that
Even though mesothelioma is rare as cancers go, researchers have paid it quite a bit of attention over the years. They want to understand this unusually aggressive cancer so that they can find a cure. Or, if they can’t find a cure, then they want to find better therapies to help mesothelioma patients live as
A toast to long life seems appropriate in light of what researchers from the University of Rome, Italy, think they have learned about mesothelioma and wine. Writing in the journal Nutrients, the scientists asserted that polyphenols appear to beneficially alter the immune system and thereby curb production of inflammation mediators. This alteration seems to set
The quest for novel ways of attacking mesothelioma took an interesting turn recently. Researchers from Europe and the Middle East found that tumor suppressor ERβ does not do its job in the presence of high levels of a particular enzyme. The enzyme at issue is AKT1. As it so happens, mesothelioma patients typically have an
Researchers preparing to conduct a Phase 3 clinical trial of the mesothelioma drug nintedanib have officially enrolled their first mesothelioma patient. Eventually, close to 400 others will be signed up. The researchers say they intend to use this study to see how well nintedanib works for patients with unresectable malignant pleural mesothelioma. They said the
